Pharming Group (NASDAQ:PHAR) Sees Significant Decline in Short Interest

Pharming Group (NASDAQ:PHAR - Get Free Report) was the target of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 1,600 shares, a decrease of 36.0% from the March 31st total of 2,500 shares. Based on an average trading volume of 6,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the company's stock are short sold.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 20th. Oppenheimer increased their target price on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 47,997 shares of the company's stock after acquiring an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.03% of the company's stock.

Pharming Group Stock Up 1.3 %

NASDAQ PHAR traded up $0.11 on Thursday, hitting $8.88. 2,394 shares of the company were exchanged, compared to its average volume of 6,402. Pharming Group has a 12 month low of $6.65 and a 12 month high of $11.07. The company has a market cap of $604.12 million, a PE ratio of -34.15 and a beta of -0.08. The stock has a fifty day moving average of $8.44 and a 200-day moving average of $8.69. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The business had revenue of $92.70 million during the quarter, compared to analyst estimates of $76.67 million. As a group, analysts forecast that Pharming Group will post -0.2 earnings per share for the current year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.